BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Power DG, Shah MA, Asmis TR., Garcia JJ., Kemeny NE. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs 2010;28:353-60. [DOI: 10.1007/s10637-009-9268-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Rolfo C, Bronte G, Passiglia F, Papadimitriou K, Russo A, Peeters M. Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2013;9:250-60. [DOI: 10.1007/s11888-013-0174-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Sartore-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. Cancer Treat Rev 2016;51:54-62. [PMID: 27865140 DOI: 10.1016/j.ctrv.2016.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
3 Solduzian M, Anvari S, Taghvaye Masoumi H, Shahi F, Jahangard-Rafsanjani Z. Successful desensitization of a patient with cetuximab hypersensitivity: A case report. J Oncol Pharm Pract 2019;25:1726-30. [PMID: 30142983 DOI: 10.1177/1078155218793505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Faugeras L, Dili A, Druez A, Krug B, Decoster C, D’hondt L. Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy. Critical Reviews in Oncology/Hematology 2017;115:59-66. [DOI: 10.1016/j.critrevonc.2017.03.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
5 Lau SC, Chung V, Lim D, Shibata S. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: A retrospective review. J Oncol Pharm Pract 2014;20:83-7. [DOI: 10.1177/1078155212474048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer. 2010;9:315-318. [PMID: 21208847 DOI: 10.3816/ccc.2010.n.046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
7 Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 2011;11:937-49. [PMID: 21557708 DOI: 10.1517/14712598.2011.582464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
8 Sonoda H, Mekata E, Shimizu T, Endo Y, Tani T. Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. Oncol Lett 2013;5:1331-4. [PMID: 23599789 DOI: 10.3892/ol.2013.1171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
9 Izzedine H, Perazella MA. Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrol Dial Transplant 2017;32:1089-97. [PMID: 28339780 DOI: 10.1093/ndt/gfw467] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
10 Stremitzer S, Sebio A, Stintzing S, Lenz HJ. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014;13:843-851. [PMID: 24766434 DOI: 10.1517/14740338.2014.915024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 Piccirillo MC, Avallone A, Carlomagno C, Maiello E, Rosati G, Alabiso O, Nasti G, De Placido S, Latiano TP, Bilancia D, Ottaiano A, De Stefano A, Romano C, Silvestro L, Nappi A, Cassata A, Giordano P, Iaffaioli RV, Normanno N, Perrone F, Daniele B. Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. Clin Colorectal Cancer 2020;19:270-6. [PMID: 32631788 DOI: 10.1016/j.clcc.2020.05.009] [Reference Citation Analysis]
12 Hata A, Katakami N, Fujita S, Takatori K, Horai A, Kitajima N, Terashima K. Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer. J Gastrointest Cancer 2013;44:456-9. [PMID: 23212286 DOI: 10.1007/s12029-012-9453-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
13 Saleh H, Embry S, Nauli A, Atyia S, Krishnaswamy G. Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution. Clin Mol Allergy 2012;10:5. [PMID: 22397506 DOI: 10.1186/1476-7961-10-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
14 Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014;40:701-715. [PMID: 24731471 DOI: 10.1016/j.ctrv.2014.02.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
15 Ren S, Sun X, Wang H, Nguyen TH, Sadeghipour N, Xu X, Kang CS, Liu Y, Xu H, Wu N, Chen Y, Tichauer K, Minh DDL, Chong HS. Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging. ChemMedChem 2018;13:2606-17. [PMID: 30403833 DOI: 10.1002/cmdc.201800598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cortijo-Cascajares S, Jiménez-Cerezo MJ, Herreros de Tejada A. Review of hypersensitivity reactions to antineoplastic agents. Farm Hosp 2012;36:148-58. [PMID: 22484106 DOI: 10.1016/j.farma.2011.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ochenduszko SL, Krzemieniecki K. Targeted therapy in advanced colorectal cancer: more data, more questions. Anticancer Drugs. 2010;21:737-748. [PMID: 20631611 DOI: 10.1097/cad.0b013e32833cfc99] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treat Rev 2019;73:41-53. [PMID: 30616224 DOI: 10.1016/j.ctrv.2018.12.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
19 Argiles G, Dienstmann R, Elez E, Tabernero J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol 2012;8:373-89. [PMID: 22515440 DOI: 10.2217/fon.12.20] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]